Nicholas Company Inc. Has $71.73 Million Holdings in Eli Lilly and Company $LLY

Nicholas Company Inc. raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 9.4% in the second quarter, according to its most recent filing with the SEC. The firm owned 92,014 shares of the company’s stock after purchasing an additional 7,940 shares during the quarter. Eli Lilly and Company makes up approximately 1.2% of Nicholas Company Inc.’s investment portfolio, making the stock its 24th largest holding. Nicholas Company Inc.’s holdings in Eli Lilly and Company were worth $71,728,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Tredje AP fonden increased its position in Eli Lilly and Company by 18.8% during the 2nd quarter. Tredje AP fonden now owns 304,733 shares of the company’s stock valued at $237,549,000 after purchasing an additional 48,160 shares during the period. Eleva Capital SAS acquired a new stake in Eli Lilly and Company during the 2nd quarter valued at approximately $1,287,000. SS&H Financial Advisors Inc. increased its holdings in Eli Lilly and Company by 8.8% in the second quarter. SS&H Financial Advisors Inc. now owns 1,234 shares of the company’s stock worth $962,000 after purchasing an additional 100 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors increased its holdings in Eli Lilly and Company by 23.9% in the second quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors now owns 1,528 shares of the company’s stock worth $1,191,000 after purchasing an additional 295 shares in the last quarter. Finally, Elm Partners Management LLC bought a new stake in Eli Lilly and Company in the second quarter worth approximately $2,815,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of research analyst reports. Leerink Partnrs downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 7th. Daiwa Capital Markets downgraded Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price for the company. in a report on Sunday, August 17th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Eli Lilly and Company in a report on Wednesday, October 8th. Daiwa America downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. Finally, HSBC lifted their target price on Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $940.00.

Eli Lilly and Company Trading Up 2.2%

NYSE LLY opened at $862.96 on Friday. The company has a market cap of $816.76 billion, a price-to-earnings ratio of 56.40, a P/E/G ratio of 1.21 and a beta of 0.47. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $935.63. The business has a 50 day moving average price of $780.74 and a 200-day moving average price of $771.71. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. The firm had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company’s quarterly revenue was up 53.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be issued a dividend of $1.50 per share. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company’s payout ratio is currently 39.22%.

Insider Activity

In related news, Director Jamere Jackson bought 200 shares of the business’s stock in a transaction that occurred on Friday, August 8th. The shares were bought at an average price of $639.56 per share, with a total value of $127,912.00. Following the completion of the transaction, the director directly owned 9,402 shares in the company, valued at approximately $6,013,143.12. This represents a 2.17% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO David A. Ricks bought 1,632 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the transaction, the chief executive officer owned 546,601 shares of the company’s stock, valued at $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have purchased 4,514 shares of company stock valued at $2,894,841. Corporate insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.